查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球药物警戒市场—增长、未来展望、竞争分析 (2022-2030)
市场调查报告书
商品编码
1180743

全球药物警戒市场—增长、未来展望、竞争分析 (2022-2030)

Pharmacovigilance Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030
出版日期: | 出版商: Acute Market Reports | 英文 115 Pages | 商品交期: 最快1-2个工作天内

价格

在 2022 年至 2030 年的预测期内，全球药物警戒市场规模预计将以 13.5% 的复合年增长率增长。 不良事件激增和慢性病（糖尿病、癌症等）发病率上升导致药物消费增加，是推动药物警戒市场增长的一些主要驱动因素。

本报告考察了全球药物警戒市场，并提供了市场趋势、竞争信息、细分市场分析、新兴趋势、技术分析和公司概况等信息。

内容

第一章前言

  • 报告概述
  • 市场细分
  • 调查方法

第 2 章执行摘要

  • 市场概况:全球药物警戒市场
  • 全球药物警戒市场:按临床试验阶段分类（2021 年）
  • 按方法类型划分的全球药物警戒市场（2021 年）
  • 按最终用户类型分列的全球药物警戒市场（2021 年）
  • 按服务提供商类型划分的全球药物警戒市场（2021 年）
  • 全球药物警戒市场:按治疗领域分类（2021 年）
  • 按地区分列的全球药物警戒市场（2021 年）
  • 有吸引力的投资建议:按地区（2021 年）

第 3 章药物警戒市场:竞争分析

  • 主要药物警戒市场供应商的市场定位
  • 药物警戒市场供应商招募策略
  • 主要行业战略
  • 分层分析:2021 年与 2030 年

第 4 章药物警戒市场:宏观分析和市场动态

  • 介绍
  • 世界药物警戒市场价值（2020-2030 年）
  • 市场动态
    • 市场驱动力
    • 市场製约因素
    • 主要问题
    • 主要机会
  • 促进因素和抑制因素的影响分析
  • 跷跷板分析

第 5 章药物警戒市场:按临床试验阶段 (2020-2030)

  • 市场概览
  • 增长和收益分析:2021 年与 2030 年
  • 市场细分
    • 临床前动物毒性
    • 临床试验第一阶段
    • 临床试验二期
    • III 期临床试验
    • 上市后监督

第 6 章药物警戒市场:按方法类型分类 (2020-2030)

  • 市场概览
  • 增长和收益分析:2021 年与 2030 年
  • 市场细分
    • 自愿报告
    • 增强的副作用报告
    • 有针对性的报告
    • 队列事件监控
    • 电子病历监控

第 7 章药物警戒市场:按最终用户类型分类，2020-2030

  • 市场概览
  • 增长和收益分析:2021 年与 2030 年
  • 市场细分
    • 内部
    • 合同外包

第 8 章药物警戒市场:按服务提供商类型分类，2020-2030

  • 市场概览
  • 增长和收益分析:2021 年与 2030 年
  • 市场细分
    • 医院
    • 製药公司
    • 其他

第 9 章药物警戒市场:按治疗领域（2020-2030 年）

  • 市场概览
  • 增长和收益分析:2021 年与 2030 年
  • 市场细分
    • 肿瘤科
    • 心脏病学
    • 呼吸系统
    • 其他

第 10 章北美药物警戒市场 2020-2030

  • 市场概览
  • 药物警戒市场:按临床试验阶段 (2020-2030)
  • 按方法类型划分的药物警戒市场（2020 年至 2030 年）
  • 药物警戒市场:按最终用户类型分类 (2020-2030)
  • 按服务提供商类型划分的药物警戒市场（2020-2030 年）
  • 药物警戒市场:按治疗领域分类（2020-2030 年）
  • 按地区分列的药物警戒市场（2020-2030 年）
    • 北美

第 11 章英国/欧盟药物警戒市场 2020-2030

  • 市场概览
  • 药物警戒市场:按临床试验阶段 (2020-2030)
  • 按方法类型划分的药物警戒市场（2020 年至 2030 年）
  • 药物警戒市场:按最终用户类型分类 (2020-2030)
  • 按服务提供商类型划分的药物警戒市场（2020-2030 年）
  • 药物警戒市场:按治疗领域分类（2020-2030 年）
  • 按地区分列的药物警戒市场（2020-2030 年）
    • 英国/欧盟

第 12 章亚太药物警戒市场 2020-2030

  • 市场概览
  • 药物警戒市场:按临床试验阶段 (2020-2030)
  • 按方法类型划分的药物警戒市场（2020 年至 2030 年）
  • 药物警戒市场:按最终用户类型分类 (2020-2030)
  • 按服务提供商类型划分的药物警戒市场（2020-2030 年）
  • 药物警戒市场:按治疗领域分类（2020-2030 年）
  • 按地区分列的药物警戒市场（2020-2030 年）
    • 亚太地区

第 13 章拉丁美洲药物警戒市场 2020-2030

  • 市场概览
  • 药物警戒市场:按临床试验阶段 (2020-2030)
  • 按方法类型划分的药物警戒市场（2020 年至 2030 年）
  • 药物警戒市场:按最终用户类型分类 (2020-2030)
  • 按服务提供商类型划分的药物警戒市场（2020-2030 年）
  • 药物警戒市场:按治疗领域分类（2020-2030 年）
  • 按地区分列的药物警戒市场（2020-2030 年）
    • 拉丁美洲

第 14 章中东和非洲的药物警戒市场（2020-2030 年）

  • 市场概览
  • 药物警戒市场:按临床试验阶段 (2020-2030)
  • 按方法类型划分的药物警戒市场（2020 年至 2030 年）
  • 药物警戒市场:按最终用户类型分类 (2020-2030)
  • 按服务提供商类型划分的药物警戒市场（2020-2030 年）
  • 药物警戒市场:按治疗领域分类（2020-2030 年）
  • 按地区分列的药物警戒市场（2020-2030 年）
    • 中东和非洲

第十五章公司简介

  • Accenture
  • BoehringerIngelheim
  • Bristol-Myers Squibb
  • Clinquest Group B.V.
  • Cognizant Technology Solutions Corporation
  • EcronAcunova Ltd.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline
  • HCL Technologies
  • IBM Corporation
Product Code: 136781-08-22

The pharmacovigilance (phv) market is anticipated to grow at a compound annual growth rate of 13.5% for the forecasted period (2022 - 2030). As the world's population ages, chronic diseases have increased; and more adverse drug reactions mean more pharmacovigilance. Pharmacovigilance (drug safety) is the healthcare industry's effort to ensure that pharmaceutical companies' claims are accurate and supported by scientific evidence. This report covers all the quantitative and qualitative aspects of pharmacovigilance market and also talks about its key drivers, the challenges it faces, the growth opportunities present in the market, and its future prospects.

Post Marketing Surveillance Phase Takes the Largest Slice

The market has been segmented on basis of Clinical Trial Phases, Service Providers, End Users, Methods, and Regional Basis. On the basis of Clinical Trials, Phase IV i.e. Post Marketing Surveillance Phase has a presiding share of about 75.6% for the year 2020 whereas On the basis of Service Provider, Contract Outsourcing has a presiding share of about 59.2%. Spontaneous Reporting has a dominant share of 30.3% for the year 2020 because of its usefulness in detecting new, serious and rare adverse drug reaction cases and moreover it is an efficient and inexpensive method of reporting ADRs. After Spontaneous Reporting, Cohort Event Monitoring is expected to show growth exponentially over a forecast period. While viewing Phv Market on basis of therapeutic areas, oncology (The study and Treatment of Tumours) dominates the market with a share of about 26.5% whereas while viewing it on basis of end Users, pharmaceuticals dominates the market with a share of 42.6%.

Pharmacovigilance Market: Drivers and Challenges

The surge in cases of Adverse drug reaction (ADR), the increasing occurrence of Chronic Diseases (Diabetes, Cancer, etc.) which in turn lead to increased drug consumption are a few of the main underlying forces driving the growth of the Phv Market. 5% of hospitalizations in Europe and the U.S.in the year 2019 were due to adverse drug reaction cases. Iatrogenic disease is the most common disease caused due to adverse drug reactions.

According to a study by Tufts University, 40% of Adverse Drug Events are never reported by Healthcare Professionals. Another major problem in Spontaneous Reporting of Adverse drug events (ADE) is misreporting and miscoding of reports. The data mentioned in reports under the fields of dosage, formulation type, time, and length of exposure to ADE is not clearly stated.

Pharmacovigilance Market: Key Player and Market

For the year 2020, North America dominated the Pharmacovigilance Market with a fair share of about 34% due to the presence of key pharmaceuticals and MDMs (Medical Device Players) whereas the Asia Pacific is anticipated to have a compound annual growth rate of 13.5% attributable to its accessibility of various outsourcing organizations. Industry leaders are targeting on developing research and development activities, new product launches, collaborating with leading Pharmaceutical companies in order to spread awareness about proper use of medicines and having access to medical information.Few of the pharmacovigilance market's key players are- BoehringerIngelheim, Bristol-Myers Squibb, Clinquest Group B.V., EcronAcunova Ltd., F. Hoffmann-La Roche Ltd., GlaxoSmithKline, HCL Technologies, Accenture, Cognizant, IBM Corporation, Wipro Limited.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Pharmacovigilance market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Pharmacovigilance market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Market Segmentation

Clinical Trial Phase

Preclinical Animal Toxicity

Clinical Trial Phase I

Clinical Trial Phase II

Clinical Trial Phase III

Post Marketing Surveillance

Type of Method

Spontaneous Reporting

Intensified Adverse Drug Reaction Reporting

Targeted Reporting

Cohort Event Monitoring

EHR Monitoring

Type of End User

In-House

Contract Outsourcing

Type of Service Provider

Hospitals

Pharmaceutical Companies

Others

Therapeutic Area

Oncology

Cardiology

Respiratory Systems

Others

Region Segment (2020-2030; US$ Million)

North America

U.S.

Canada

Rest of North America

UK and European Union

UK

Germany

Spain

Italy

France

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East and Africa

GCC

Africa

Rest of Middle East and Africa

Global Impact of COVID-19 Segment (2020-2021; US$ Million )

Pre COVID-19 situation

Post COVID-19 situation

Key questions answered in this report:

What are the key micro and macro environmental factors that are impacting the growth of Pharmacovigilance market?

What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?

Estimated forecast and market projections up to 2030.

Which segment accounts for the fastest CAGR during the forecast period?

Which market segment holds a larger market share and why?

Are low and middle-income economies investing in the Pharmacovigilance market?

Which is the largest regional market for Pharmacovigilance market?

What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

Which are the key trends driving Pharmacovigilance market growth?

Who are the key competitors and what are their key strategies to enhance their market presence in the Pharmacovigilance market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Pharmacovigilance Market
  • 2.2. Global Pharmacovigilance Market, By Clinical Trial Phase, 2021 (US$ Million)
  • 2.3. Global Pharmacovigilance Market, By Type of Method, 2021 (US$ Million)
  • 2.4. Global Pharmacovigilance Market, By Type of End User, 2021 (US$ Million)
  • 2.5. Global Pharmacovigilance Market, By Type of Service Provider, 2021 (US$ Million)
  • 2.6. Global Pharmacovigilance Market, By Therapeutic Area, 2021 (US$ Million)
  • 2.7. Global Pharmacovigilance Market, By Geography, 2021 (US$ Million)
  • 2.8. Attractive Investment Proposition by Geography, 2021

3. Pharmacovigilance Market: Competitive Analysis

  • 3.1. Market Positioning of Key Pharmacovigilance Market Vendors
  • 3.2. Strategies Adopted by Pharmacovigilance Market Vendors
  • 3.3. Key Industry Strategies
  • 3.4. Tier Analysis 2021 Versus 2030

4. Pharmacovigilance Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Pharmacovigilance Market Value, 2020 - 2030, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis

5. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 5.3. Market Segmentation
    • 5.3.1. Preclinical Animal Toxicity
    • 5.3.2. Clinical Trial Phase I
    • 5.3.3. Clinical Trial Phase II
    • 5.3.4. Clinical Trial Phase III
    • 5.3.5. Post Marketing Surveillance

6. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)

  • 6.1. Market Overview
  • 6.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 6.3. Market Segmentation
    • 6.3.1. Spontaneous Reporting
    • 6.3.2. Intensified Adverse Drug Reaction Reporting
    • 6.3.3. Targeted Reporting
    • 6.3.4. Cohort Event Monitoring
    • 6.3.5. EHR Monitoring

7. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)

  • 7.1. Market Overview
  • 7.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 7.3. Market Segmentation
    • 7.3.1. In-House
    • 7.3.2. Contract Outsourcing

8. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)

  • 8.1. Market Overview
  • 8.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 8.3. Market Segmentation
    • 8.3.1. Hospitals
    • 8.3.2. Pharmaceutical Companies
    • 8.3.3. Others

9. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)

  • 9.1. Market Overview
  • 9.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 9.3. Market Segmentation
    • 9.3.1. Oncology
    • 9.3.2. Cardiology
    • 9.3.3. Respiratory Systems
    • 9.3.4. Others

10. North America Pharmacovigilance Market, 2020-2030, USD (Million)

  • 10.1. Market Overview
  • 10.2. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
  • 10.3. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
  • 10.4. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
  • 10.5. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
  • 10.6. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
  • 10.7.Pharmacovigilance Market: By Region, 2020-2030, USD (Million)
    • 10.7.1.North America
      • 10.7.1.1. U.S.
        • 10.7.1.1.1. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
        • 10.7.1.1.1. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
        • 10.7.1.1.1. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
        • 10.7.1.1.1. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
        • 10.7.1.1.1. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
      • 10.7.1.2. Canada
        • 10.7.1.2.1. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
        • 10.7.1.2.1. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
        • 10.7.1.2.1. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
        • 10.7.1.2.1. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
        • 10.7.1.2.1. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
      • 10.7.1.3. Rest of North America
        • 10.7.1.3.1. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
        • 10.7.1.3.1. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
        • 10.7.1.3.1. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
        • 10.7.1.3.1. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
        • 10.7.1.3.1. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)

11. UK and European Union Pharmacovigilance Market, 2020-2030, USD (Million)

  • 11.1. Market Overview
  • 11.2. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
  • 11.3. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
  • 11.4. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
  • 11.5. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
  • 11.6. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
  • 11.7.Pharmacovigilance Market: By Region, 2020-2030, USD (Million)
    • 11.7.1.UK and European Union
      • 11.7.1.1. UK
        • 11.7.1.1.1. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
        • 11.7.1.1.1. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
        • 11.7.1.1.1. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
        • 11.7.1.1.1. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
        • 11.7.1.1.1. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
      • 11.7.1.2. Germany
        • 11.7.1.2.1. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
        • 11.7.1.2.1. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
        • 11.7.1.2.1. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
        • 11.7.1.2.1. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
        • 11.7.1.2.1. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
      • 11.7.1.3. Spain
        • 11.7.1.3.1. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
        • 11.7.1.3.1. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
        • 11.7.1.3.1. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
        • 11.7.1.3.1. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
        • 11.7.1.3.1. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
      • 11.7.1.4. Italy
        • 11.7.1.4.1. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
        • 11.7.1.4.1. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
        • 11.7.1.4.1. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
        • 11.7.1.4.1. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
        • 11.7.1.4.1. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
      • 11.7.1.5. France
        • 11.7.1.5.1. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
        • 11.7.1.5.1. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
        • 11.7.1.5.1. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
        • 11.7.1.5.1. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
        • 11.7.1.5.1. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
      • 11.7.1.6. Rest of Europe
        • 11.7.1.6.1. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
        • 11.7.1.6.1. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
        • 11.7.1.6.1. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
        • 11.7.1.6.1. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
        • 11.7.1.6.1. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)

12. Asia Pacific Pharmacovigilance Market, 2020-2030, USD (Million)

  • 12.1. Market Overview
  • 12.2. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
  • 12.3. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
  • 12.4. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
  • 12.5. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
  • 12.6. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
  • 12.7.Pharmacovigilance Market: By Region, 2020-2030, USD (Million)
    • 12.7.1.Asia Pacific
      • 12.7.1.1. China
        • 12.7.1.1.1. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
        • 12.7.1.1.1. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
        • 12.7.1.1.1. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
        • 12.7.1.1.1. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
        • 12.7.1.1.1. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
      • 12.7.1.2. Japan
        • 12.7.1.2.1. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
        • 12.7.1.2.1. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
        • 12.7.1.2.1. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
        • 12.7.1.2.1. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
        • 12.7.1.2.1. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
      • 12.7.1.3. India
        • 12.7.1.3.1. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
        • 12.7.1.3.1. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
        • 12.7.1.3.1. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
        • 12.7.1.3.1. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
        • 12.7.1.3.1. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
      • 12.7.1.4. Australia
        • 12.7.1.4.1. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
        • 12.7.1.4.1. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
        • 12.7.1.4.1. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
        • 12.7.1.4.1. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
        • 12.7.1.4.1. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
      • 12.7.1.5. South Korea
        • 12.7.1.5.1. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
        • 12.7.1.5.1. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
        • 12.7.1.5.1. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
        • 12.7.1.5.1. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
        • 12.7.1.5.1. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
      • 12.7.1.6. Rest of Asia Pacific
        • 12.7.1.6.1. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
        • 12.7.1.6.1. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
        • 12.7.1.6.1. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
        • 12.7.1.6.1. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
        • 12.7.1.6.1. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)

13. Latin America Pharmacovigilance Market, 2020-2030, USD (Million)

  • 13.1. Market Overview
  • 13.2. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
  • 13.3. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
  • 13.4. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
  • 13.5. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
  • 13.6. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
  • 13.7.Pharmacovigilance Market: By Region, 2020-2030, USD (Million)
    • 13.7.1.Latin America
      • 13.7.1.1. Brazil
        • 13.7.1.1.1. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
        • 13.7.1.1.1. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
        • 13.7.1.1.1. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
        • 13.7.1.1.1. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
        • 13.7.1.1.1. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
      • 13.7.1.2. Mexico
        • 13.7.1.2.1. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
        • 13.7.1.2.1. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
        • 13.7.1.2.1. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
        • 13.7.1.2.1. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
        • 13.7.1.2.1. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
      • 13.7.1.3. Rest of Latin America
        • 13.7.1.3.1. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
        • 13.7.1.3.1. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
        • 13.7.1.3.1. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
        • 13.7.1.3.1. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
        • 13.7.1.3.1. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)

14. Middle East and Africa Pharmacovigilance Market, 2020-2030, USD (Million)

  • 14.1. Market Overview
  • 14.2. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
  • 14.3. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
  • 14.4. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
  • 14.5. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
  • 14.6. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
  • 14.7.Pharmacovigilance Market: By Region, 2020-2030, USD (Million)
    • 14.7.1.Middle East and Africa
      • 14.7.1.1. GCC
        • 14.7.1.1.1. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
        • 14.7.1.1.1. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
        • 14.7.1.1.1. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
        • 14.7.1.1.1. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
        • 14.7.1.1.1. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
      • 14.7.1.2. Africa
        • 14.7.1.2.1. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
        • 14.7.1.2.1. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
        • 14.7.1.2.1. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
        • 14.7.1.2.1. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
        • 14.7.1.2.1. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
      • 14.7.1.3. Rest of Middle East and Africa
        • 14.7.1.3.1. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
        • 14.7.1.3.1. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
        • 14.7.1.3.1. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
        • 14.7.1.3.1. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
        • 14.7.1.3.1. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)

15. Company Profile

  • 15.1. Accenture
    • 15.1.1. Company Overview
    • 15.1.2. Financial Performance
    • 15.1.3. Product Portfolio
    • 15.1.4. Strategic Initiatives
  • 15.2. BoehringerIngelheim
    • 15.2.1. Company Overview
    • 15.2.2. Financial Performance
    • 15.2.3. Product Portfolio
    • 15.2.4. Strategic Initiatives
  • 15.3. Bristol-Myers Squibb
    • 15.3.1. Company Overview
    • 15.3.2. Financial Performance
    • 15.3.3. Product Portfolio
    • 15.3.4. Strategic Initiatives
  • 15.4. Clinquest Group B.V.
    • 15.4.1. Company Overview
    • 15.4.2. Financial Performance
    • 15.4.3. Product Portfolio
    • 15.4.4. Strategic Initiatives
  • 15.5. Cognizant Technology Solutions Corporation
    • 15.5.1. Company Overview
    • 15.5.2. Financial Performance
    • 15.5.3. Product Portfolio
    • 15.5.4. Strategic Initiatives
  • 15.6. EcronAcunova Ltd.
    • 15.6.1. Company Overview
    • 15.6.2. Financial Performance
    • 15.6.3. Product Portfolio
    • 15.6.4. Strategic Initiatives
  • 15.7. F. Hoffmann-La Roche Ltd.
    • 15.7.1. Company Overview
    • 15.7.2. Financial Performance
    • 15.7.3. Product Portfolio
    • 15.7.4. Strategic Initiatives
  • 15.8. GlaxoSmithKline
    • 15.8.1. Company Overview
    • 15.8.2. Financial Performance
    • 15.8.3. Product Portfolio
    • 15.8.4. Strategic Initiatives
  • 15.9. HCL Technologies
    • 15.9.1. Company Overview
    • 15.9.2. Financial Performance
    • 15.9.3. Product Portfolio
    • 15.9.4. Strategic Initiatives
  • 15.10. IBM Corporation
    • 15.10.1. Company Overview
    • 15.10.2. Financial Performance
    • 15.10.3. Product Portfolio
    • 15.10.4. Strategic Initiatives

List of Tables

  • TABLE 1 Global Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
  • TABLE 2 Global Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
  • TABLE 3 Global Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
  • TABLE 4 Global Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
  • TABLE 5 Global Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
  • TABLE 6 North America Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
  • TABLE 7 North America Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
  • TABLE 8 North America Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
  • TABLE 9 North America Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
  • TABLE 10 North America Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
  • TABLE 11 U.S. Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
  • TABLE 12 U.S. Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
  • TABLE 13 U.S. Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
  • TABLE 14 U.S. Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
  • TABLE 15 U.S. Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
  • TABLE 16 Canada Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
  • TABLE 17 Canada Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
  • TABLE 18 Canada Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
  • TABLE 19 Canada Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
  • TABLE 20 Canada Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
  • TABLE 21 Rest of North America Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
  • TABLE 22 Rest of North America Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
  • TABLE 23 Rest of North America Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
  • TABLE 24 Rest of North America Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
  • TABLE 25 Rest of North America Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
  • TABLE 26 UK and European Union Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
  • TABLE 27 UK and European Union Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
  • TABLE 28 UK and European Union Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
  • TABLE 29 UK and European Union Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
  • TABLE 30 UK and European Union Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
  • TABLE 31 UK Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
  • TABLE 32 UK Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
  • TABLE 33 UK Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
  • TABLE 34 UK Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
  • TABLE 35 UK Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
  • TABLE 36 Germany Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
  • TABLE 37 Germany Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
  • TABLE 38 Germany Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
  • TABLE 39 Germany Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
  • TABLE 40 Germany Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
  • TABLE 41 Spain Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
  • TABLE 42 Spain Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
  • TABLE 43 Spain Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
  • TABLE 44 Spain Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
  • TABLE 45 Spain Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
  • TABLE 46 Italy Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
  • TABLE 47 Italy Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
  • TABLE 48 Italy Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
  • TABLE 49 Italy Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
  • TABLE 50 Italy Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
  • TABLE 51 France Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
  • TABLE 52 France Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
  • TABLE 53 France Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
  • TABLE 54 France Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
  • TABLE 55 France Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
  • TABLE 56 Rest of Europe Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
  • TABLE 57 Rest of Europe Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
  • TABLE 58 Rest of Europe Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
  • TABLE 59 Rest of Europe Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
  • TABLE 60 Rest of Europe Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
  • TABLE 61 Asia Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
  • TABLE 62 Asia Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
  • TABLE 63 Asia Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
  • TABLE 64 Asia Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
  • TABLE 65 Asia Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
  • TABLE 66 China Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
  • TABLE 67 China Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
  • TABLE 68 China Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
  • TABLE 69 China Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
  • TABLE 70 China Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
  • TABLE 71 Japan Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
  • TABLE 72 Japan Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
  • TABLE 73 Japan Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
  • TABLE 74 Japan Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
  • TABLE 75 Japan Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
  • TABLE 76 India Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
  • TABLE 77 India Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
  • TABLE 78 India Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
  • TABLE 79 India Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
  • TABLE 80 India Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
  • TABLE 81 Australia Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
  • TABLE 82 Australia Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
  • TABLE 83 Australia Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
  • TABLE 84 Australia Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
  • TABLE 85 Australia Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
  • TABLE 86 South Korea Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
  • TABLE 87 South Korea Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
  • TABLE 88 South Korea Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
  • TABLE 89 South Korea Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
  • TABLE 90 South Korea Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
  • TABLE 91 Latin America Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
  • TABLE 92 Latin America Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
  • TABLE 93 Latin America Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
  • TABLE 94 Latin America Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
  • TABLE 95 Latin America Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
  • TABLE 96 Brazil Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
  • TABLE 97 Brazil Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
  • TABLE 98 Brazil Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
  • TABLE 99 Brazil Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
  • TABLE 100 Brazil Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
  • TABLE 101 Mexico Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
  • TABLE 102 Mexico Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
  • TABLE 103 Mexico Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
  • TABLE 104 Mexico Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
  • TABLE 105 Mexico Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
  • TABLE 106 Rest of Latin America Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
  • TABLE 107 Rest of Latin America Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
  • TABLE 108 Rest of Latin America Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
  • TABLE 109 Rest of Latin America Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
  • TABLE 110 Rest of Latin America Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
  • TABLE 111 Middle East and Africa Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
  • TABLE 112 Middle East and Africa Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
  • TABLE 113 Middle East and Africa Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
  • TABLE 114 Middle East and Africa Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
  • TABLE 115 Middle East and Africa Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
  • TABLE 116 GCC Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
  • TABLE 117 GCC Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
  • TABLE 118 GCC Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
  • TABLE 119 GCC Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
  • TABLE 120 GCC Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
  • TABLE 121 Africa Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
  • TABLE 122 Africa Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
  • TABLE 123 Africa Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
  • TABLE 124 Africa Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
  • TABLE 125 Africa Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
  • TABLE 126 Rest of Middle East and Africa Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
  • TABLE 127 Rest of Middle East and Africa Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
  • TABLE 128 Rest of Middle East and Africa Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
  • TABLE 129 Rest of Middle East and Africa Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
  • TABLE 130 Rest of Middle East and Africa Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)

List of Figures

  • FIG. 1 Global Pharmacovigilance Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Pharmacovigilance Market: Quality Assurance
  • FIG. 5 Global Pharmacovigilance Market, By Clinical Trial Phase, 2021
  • FIG. 6 Global Pharmacovigilance Market, By Type of Method, 2021
  • FIG. 7 Global Pharmacovigilance Market, By Type of End User, 2021
  • FIG. 8 Global Pharmacovigilance Market, By Type of Service Provider, 2021
  • FIG. 9 Global Pharmacovigilance Market, By Therapeutic Area, 2021
  • FIG. 10 Global Pharmacovigilance Market, By Geography, 2021
  • FIG. 11 Market Geographical Opportunity Matrix - Global Pharmacovigilance Market, 2021
  • FIG. 12 Market Positioning of Key Pharmacovigilance Market Players, 2021
  • FIG. 13 Global Pharmacovigilance Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
  • FIG. 14 Global Pharmacovigilance Market, By Clinical Trial Phase, 2021 Vs 2030, %
  • FIG. 15 Global Pharmacovigilance Market, By Type of Method, 2021 Vs 2030, %
  • FIG. 16 Global Pharmacovigilance Market, By Type of End User, 2021 Vs 2030, %
  • FIG. 17 Global Pharmacovigilance Market, By Type of Service Provider, 2021 Vs 2030, %
  • FIG. 18 Global Pharmacovigilance Market, By Therapeutic Area, 2021 Vs 2030, %
  • FIG. 19 U.S. Pharmacovigilance Market (US$ Million), 2020 - 2030
  • FIG. 20 Canada Pharmacovigilance Market (US$ Million), 2020 - 2030
  • FIG. 21 Rest of North America Pharmacovigilance Market (US$ Million), 2020 - 2030
  • FIG. 22 UK Pharmacovigilance Market (US$ Million), 2020 - 2030
  • FIG. 23 Germany Pharmacovigilance Market (US$ Million), 2020 - 2030
  • FIG. 24 Spain Pharmacovigilance Market (US$ Million), 2020 - 2030
  • FIG. 25 Italy Pharmacovigilance Market (US$ Million), 2020 - 2030
  • FIG. 26 France Pharmacovigilance Market (US$ Million), 2020 - 2030
  • FIG. 27 Rest of Europe Pharmacovigilance Market (US$ Million), 2020 - 2030
  • FIG. 28 China Pharmacovigilance Market (US$ Million), 2020 - 2030
  • FIG. 29 Japan Pharmacovigilance Market (US$ Million), 2020 - 2030
  • FIG. 30 India Pharmacovigilance Market (US$ Million), 2020 - 2030
  • FIG. 31 Australia Pharmacovigilance Market (US$ Million), 2020 - 2030
  • FIG. 32 South Korea Pharmacovigilance Market (US$ Million), 2020 - 2030
  • FIG. 33 Rest of Asia Pharmacovigilance Market (US$ Million), 2020 - 2030
  • FIG. 34 Brazil Pharmacovigilance Market (US$ Million), 2020 - 2030
  • FIG. 35 Mexico Pharmacovigilance Market (US$ Million), 2020 - 2030
  • FIG. 36 Rest of Latin America Pharmacovigilance Market (US$ Million), 2020 - 2030
  • FIG. 37 GCC Pharmacovigilance Market (US$ Million), 2020 - 2030
  • FIG. 38 Africa Pharmacovigilance Market (US$ Million), 2020 - 2030
  • FIG. 39 Rest of Middle East and Africa Pharmacovigilance Market (US$ Million), 2020 - 2030